Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Akoya Biosciences Inc (AKYA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: AKYA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Year Target Price $1.88
Year Target Price $1.88
| 0 | Strong Buy |
| 0 | Buy |
| 7 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.38% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 61.94M USD | Price to earnings Ratio - | 1Y Target Price 1.51 |
Price to earnings Ratio - | 1Y Target Price 1.51 | ||
Volume (30-day avg) - | Beta 1.35 | 52 Weeks Range 0.93 - 3.42 | Updated Date 06/29/2025 |
52 Weeks Range 0.93 - 3.42 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -59.45% | Operating Margin (TTM) -79.73% |
Management Effectiveness
Return on Assets (TTM) -17.49% | Return on Equity (TTM) -354.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 121619015 | Price to Sales(TTM) 0.77 |
Enterprise Value 121619015 | Price to Sales(TTM) 0.77 | ||
Enterprise Value to Revenue 1.52 | Enterprise Value to EBITDA -6.83 | Shares Outstanding 49954200 | Shares Floating 12589049 |
Shares Outstanding 49954200 | Shares Floating 12589049 | ||
Percent Insiders 72.58 | Percent Institutions 69.8 |
Analyst Ratings
Rating 3 | Target Price 1.88 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 7 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Akoya Biosciences Inc
Company Overview
History and Background
Akoya Biosciences Inc. was founded in 2015 as a spin-out from PerkinElmer's imaging business. It focuses on developing and commercializing spatial biology solutions to improve drug discovery and clinical research.
Core Business Areas
- Spatial Biology Platforms: Provides high-plex spatial imaging solutions, including instruments, reagents, and software for visualizing and analyzing cells and tissues at single-cell resolution.
- Services and Consumables: Offers contract research services, including assay development, imaging, and data analysis, along with the sale of reagents and consumables used in spatial biology workflows.
Leadership and Structure
Brian McKelligon serves as CEO. The company has a functional organizational structure with departments focusing on R&D, sales, marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- CODEX System: A highly multiplexed immunofluorescence imaging platform that allows researchers to visualize and quantify up to 40 different protein markers simultaneously. The revenue specifically from CODEX is not publicly broken out. Competitors include NanoString Technologies' GeoMx Digital Spatial Profiler and 10x Genomics' Xenium platform.
- Phenoptics Platform: An automated, high-throughput imaging system used for multiplexed immunofluorescence analysis of tissue samples. The revenue specifically from Phenoptics is not publicly broken out. Competitors include Lunaphore.
- Spatial Phenotyping Services: Provide comprehensive services related to the use of Akoya platforms and software that enables researchers to outsource experiments. Revenue from services contributes significantly to the overall revenue stream. Competitors include contract research organizations (CROs) specializing in spatial biology.
Market Dynamics
Industry Overview
The spatial biology market is rapidly growing due to increasing demand for high-resolution, multi-parametric analysis of cells and tissues in various applications, including oncology, immunology, and neuroscience.
Positioning
Akoya Biosciences Inc. is a leading player in the spatial biology market, offering comprehensive solutions that combine imaging platforms, reagents, and software. It holds a competitive advantage through its established technology and strong customer base.
Total Addressable Market (TAM)
The total addressable market for spatial biology is estimated to be in the billions of dollars. Akoya is well-positioned to capture a significant portion of this market due to its comprehensive solutions.
Upturn SWOT Analysis
Strengths
- Strong product portfolio in spatial biology
- Established customer base
- Proprietary CODEX and Phenoptics platforms
- Experienced management team
- First Mover Advantage
Weaknesses
- High operating expenses
- Reliance on key products and platforms
- Limited profitability
- Competition from larger, more established companies
Opportunities
- Expanding applications of spatial biology in drug discovery and clinical research
- Increasing demand for multi-omics analysis
- Strategic partnerships and collaborations
- Geographic expansion into emerging markets
- Acquisition of complementary technologies
Threats
- Intense competition from other spatial biology companies
- Technological advancements by competitors
- Regulatory hurdles for new products
- Economic downturn impacting research budgets
- IP infringements by competitors
Competitors and Market Share
Key Competitors
- NANO
- TXG
- LUNR
Competitive Landscape
Akoya Biosciences Inc. competes with a mix of established and emerging companies in the spatial biology market. It benefits from its early mover advantage and comprehensive solutions, but faces challenges from larger, more established companies.
Major Acquisitions
Cell IDx
- Year: 2021
- Acquisition Price (USD millions): 56
- Strategic Rationale: Expanded Akoyau2019s offerings with validated antibodies for use in translational and clinical research, complementing its existing spatial biology platforms.
Growth Trajectory and Initiatives
Historical Growth: Akoya Biosciences Inc. has experienced significant revenue growth in recent years, driven by increased adoption of its spatial biology solutions.
Future Projections: Analysts project continued revenue growth for Akoya Biosciences Inc. based on the growing demand for spatial biology and the company's strategic initiatives.
Recent Initiatives: Recent initiatives include expanding the product portfolio, forming strategic partnerships, and expanding into new geographic markets.
Summary
Akoya Biosciences is positioned to benefit from the growing spatial biology market and has a strong product portfolio. However, it faces competition from larger companies and needs to improve its profitability. Recent initiatives to expand the product portfolio and form partnerships could drive future growth and address weaknesses. The company needs to manage its operating expenses carefully to achieve profitability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- Akoya Biosciences Inc. Website
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change. Consult a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akoya Biosciences Inc
Exchange NASDAQ | Headquaters Marlborough, MA, United States | ||
IPO Launch date 2021-04-16 | President, CEO & Director Mr. Brian McKelligon | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 205 | Website https://www.akoyabio.com |
Full time employees 205 | Website https://www.akoyabio.com | ||
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. Akoya Biosciences, Inc. was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.